GRI Bio ( (GRI)) has issued an announcement. On May 14, 2026, GRI Bio reported first-quarter 2026 results and new Phase 2a data showing its IPF candidate GRI-0621 improved key clinical symptoms and ...

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivityLA JOLLA, CA, ...

GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...

GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...

More companies in Italy will be supported to disclose their impacts using the world’s leading sustainability reporting framework, following Italian becoming the latest translation of the GRI Standards ...

GRI Bio (NASDAQ:GRI) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. GRI Bio plans to offer up to 2,238,806 shares ...

The International Financial Reporting Standards Foundation and the Global Reporting Initiative said Thursday they have reached a collaboration agreement to coordinate their standard-setting and work ...